Reports

Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.

Global Uterine Fibroid Treatment Devices Market Share, Size, Analysis, Research: By Mode of Treatment: Invasive System, Non-Invasive System, Minimally Invasive System; By Techniques: Surgical Techniques, Laparoscopic Techniques, Ablation Techniques, Embolization Techniques, Others; Regional Analysis; Supplier Landscape; 2022-2030

Global Uterine Fibroid Treatment Devices Market Outlook

The global uterine fibroid treatment devices market size attained a value of USD 5.5 billion in 2021. The market value is further anticipated to grow at a CAGR of 9.5% in the forecast period of 2022-2030 to attain a value of USD 12.5 billion by 2030.

 

Company News

In July 2022, Linzagolix, which has been a promising contender for treating uterine fibroids for a long time, was discontinued, according to the Swiss women's health business ObsEva. In order to better support its current license agreements, the company will also go through a corporate restructuring process and review its development and commercialisation strategy.

 

In August 2022, Myovant & Pfizer's Myfembree received the USFDA approval for the treatment of moderate to severe pain brought on by uterine fibroids.

 

Uterine Fibroid Treatment Devices Market Insights

Fibroids are muscular tumours that get developed in the uterine wall (womb). Fibroids are benign and are usually not cancerous. The symptoms can differ from woman to woman. While some patients experience extreme symptoms like excessive menstrual bleeding, along with painful cramps, there are patients who do not experience any major symptoms.

 

Based on these symptoms, the treatment procedure for uterine fibroids is determined.

 

In the uterus, fibroids can develop into a single or multiple tumour. They can range in size from a grapefruit to an apple seed and have a rare capacity to grow extremely huge. The development of uterine fibroid increases in women in the age group of 30-40 and the fibroid sizes change post-menopause.

 

Genetic history also plays a vital role in the development of fibroids in a woman, and risk of developing fibroids is almost three times higher than average, if the patient’s mother had it.

 

Factors like weight and lifestyle also act as causative factors in the development of uterine fibroids as overweight women are more likely to have fibroids. The risk is two to three times higher than average for very overweight women and consumption of a lot of ham and red meat, such as beef, is associated with an increased chance of developing fibroids. Consuming a lot of green vegetables appears to shield females from getting fibroids.

 

Based on the location of the fibroids it is segmented into Submucosal (inside the uterine cavity), Intramural (within the wall of the uterus), Subserosal (outside the uterus), and some fibroids look like mushrooms, known as pedunculated fibroids. These mushroom like fibroids grow out from the surface or into the cavity of the uterus.

 

Fibroids do not cause any symptoms but sometimes can lead to heavy/painful bleeding, heaviness in the pelvic region, enlargement of the lower abdomen, frequent urination, painful intercourse, lower back, and leg pain, among others.

 

Fibroids with mild symptoms are usually treated with over-the-counter medication like ibuprofen or acetaminophen, and iron supplements for anemic patients. Several hormonal replacement therapies like birth control pills or progesterone injections are induced to control the symptoms of uterine fibroid. And other drugs like gonadotrophin-releasing hormone agonists through a different route of administration are also used for the treatment.

 

Fibroids with moderate to severe symptoms are treated with the following surgeries:

Myomectomy: Helps remove fibroids without removing the healthy tissues in the uterus. It is the best alternative for women who want to keep their uterus intact or who want to become pregnant following fibroids therapy. There are numerous ways to do a myomectomy. Major abdominal surgery or procedures utilising laparoscopy or hysteroscopy can be used to treat it. The kind, size, and location of the fibroids determine the kind of surgery that can be performed.

 

Hysterectomy: In this procedure, the uterus is surgically removed. The only effective treatment for uterine fibroids is this procedure. Hysterectomy carries a high risk of complications even though the procedure is often relatively safe.

 

Endometrial ablation: To stop extremely severe bleeding, the uterine lining is either removed or damaged. This can be accomplished using a laser, wire loops, microwaves, electric currents, boiling water, and other techniques.

 

Myolysis: A laparoscopy is utilised to guide the insertion of the needle into the fibroids and are then destroyed using an electric current or by freezing them.

 

Uterine Fibroid Embolization/ Uterine Artery Embolization: To supply blood to the fibroids a thin tube is threaded to the blood vessels, leading it to shrink. This procedure is best for women with heavy bleeding, pressed bladder, who do not intend to conceive in the future.

 

Uterine Fibroid Treatment Devices Market Overview

The uterine fibroid treatment devices market is further segmented into the following segments:

 

Market Breakup by Mode of Treatment

  • Invasive System
  • Non-Invasive System
  • Minimally Invasive System

 

Market Breakup by Techniques

  • Surgical Techniques
  • Hysterectomy
  • Myomectomy
  • Laparoscopic Techniques
  • Laparoscopic
  • Myolosis
  • Ablation Techniques
  • Microwave Ablation
  • Cryoablation
  • Ultrasound Ablation
  • Embolization Techniques
  • Others

 

Market Breakup by Disease Type

  • Uterine Leiomyoma (Fibroids)
  • Others

 

Market Breakup by End-User

  • Hospitals
  • Dialysis Centres
  • Others

 

Market Breakup by Region

  • North America
    • United States of America 
    • Canada 
  • Europe 
    • United Kingdom 
    • Germany 
    • France 
    • Italy 
    • Others 
  • Asia Pacific 
    • China 
    • Japan 
    • India 
    • ASEAN 
    • Australia 
    • Others 
  • Latin America 
    • Brazil 
    • Argentina 
    • Mexico 
    • Others 
  • Middle East and Africa 
    • Saudi Arabia 
    • United Arab Emirates 
    • Nigeria 
    • South Africa 
    • Others

 

Uterine Fibroid Treatment Devices Market Trends

In women of reproductive age, the uterine fibroid is a typical cause of various bleeding and pain symptoms that can negatively affect a variety of aspects of a woman's life.

 

The primary factors anticipated to propel the market are the high prevalence of uterine fibroids, along with the increased patient preference for minimally invasive procedures. The adoption of sophisticated technologies is also bolstering the growth of the uterine fibroid treatment devices market. The benign tumour of smooth muscle cells, called a uterine fibroid (UF), develops in a woman's uterus and can cause excessive menstrual flow, pelvic pain, infertility, and frequent urination.

 

The risk factors include race, age, familial predisposition, premenopausal status, hypertension, overweight, and diet, even though their etiology is still unknown. Asymptomatic uterine fibroid patients, which account for 50 to 75 percent of cases, receive less clinical attention and frequently go undetected.

 

Fibroid operations that need little to no incision are anticipated to boost the market expansion. Smaller incisions reduce post-operative pain and speed up recovery, which encourages the widespread use of these procedures. A number of significant firms are investing in R&D to bring cutting-edge minimally invasive surgical devices to uterine fibroid treatment devices market.

 

One of the incision techniques that is highly suggested by doctors is the MR-guided Focused Ultrasound (MRgFUS) used to treat uterine fibroids. Targeted tissue from the uterine cavity is heated and removed during this treatment by the device's ultrasonic beams. Since it is a non-invasive procedure, there are little to no side effects, and patients can resume their regular activities in a few days. Thus, it is projected that the demand for uterine fibroid treatment devices market would increase due to the increased demand for such operations due to their minimum pain, effectiveness, reduced risk of infection, and quick recovery as compared to open surgeries.

 

Therapeutic Landscape of Uterine Fibroid Treatment Devices Market

For the treatment of uterine fibroids, various options are available. While non-invasive or semi-invasive methods try to alleviate symptoms and eventually shrink the fibroids, medical therapy targets symptom relief.

 

The womb is surgically removed during a hysterectomy. It is the best method for preventing the recurrence of fibroids. If the patient doesn’t want to have any more children and has huge fibroids or significant bleeding, a hysterectomy may be advised.

 

A hysterectomy can be performed in a variety of ways, including through the vagina or through numerous tiny cuts (incisions) in the abdomen. Hysterectomy procedures can be done under spinal or epidural anesthesia, which numbs the lower body, depending on the technique.

 

A myomectomy is a surgical procedure to remove fibroids from the uterine wall. If the patient still wants to have children, it might be taken into consideration as an alternative to a hysterectomy. But not all fibroid types respond well to a myomectomy.

 

Depending on the size and location of the fibroids, a myomectomy may need several tiny incisions (keyhole surgery) or one larger incision in your abdomen (open surgery).

 

During a hysteroscopic excision of fibroids, fibroids are removed using a thin telescope (hysteroscope) and tiny surgical instruments. Submucosal fibroids can be removed using this method, which is acceptable for women who intend to have children in the future.

 

Hysteroscopes can be put through the vagina and into the womb through the womb entrance without making any incisions (cervix). To ensure the removal of as much fibroid tissue as feasible, several insertions are required.

 

The two surgical procedures that are used most frequently to treat uterine fibroids are hysterectomy and myomectomy. The uterus (and typically the cervix) is removed during a hysterectomy, either with or without ovarian preservation. Individual fibroids are removed during a myomectomy, leaving the uterus and the possibility of pregnancy intact.

 

Emerging Techniques and Devices in the Uterine Fibroid Treatment Devices Market

Regarding the most promising treatment, Ulipristal (UPA), the effects of the introduction of this novel class of compounds for the medical management of fibroids have been examined by numerous organisations. It has been specifically noted that a number of criteria, such as the intensity of symptoms, the characteristics of myomas, age, and a desire to retain fertility, influence the selection of a given treatment.

 

Alternatives to surgical intervention are needed in this situation, and today, selective progesterone receptor modulator (SPRM) is one such option. Two recent reviews examined the role of SPRM in the long-term medical management of hormone-dependent conditions like uterine fibroids, and they concluded that this class of compounds has emerged as an important alternative capable of providing women with effective long-term medical management and avoiding surgery entirely.

 

For symptomatic uterine fibroids, the Sonata® system offers transcervical fibroid therapy (TFA). It is a radiofrequency ablation procedure that is approved and marketed in both Europe and the United States. It is sonography-guided, non-invasive, and preserves the uterus. Sonata is a therapeutic method that combines a single-use radiofrequency ablation handpiece with a reusable intrauterine ultrasonography probe to remove uterine fibroids.

 

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the uterine fibroid treatment devices market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. Techniques like the development of instruments that can safely apply radio frequency energy to destroy fibroids have opened up a whole new world of minimally invasive possibilities for people who want to save their uterus. The companies included in this market are as follows:

 

  • Medtronic
  • Boston Scientific Corporation
  • Cooper Surgical Inc.
  • Stryker Corporation
  • Minerva Surgical, Inc.
  • AbbVie, Inc.
  • Ethicon, Inc.
  • Lumenis Ltd
  • Smith & Nephew PLC
  • Merit Medical Systems, Inc.
  • Hologic, Inc.
  • ConMed Corporation
  • Gynesonics, Inc.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2021
Historical Period 2015-2021
Forecast Period 2022-2030
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Mode of Treatment
  • Techniques
  • End-User
  • Region
Breakup by Mode of Treatment
  • Invasive System
  • Non-Invasive System
  • Minimally Invasive System
Breakup by Techniques
  • Surgical Techniques
    • Hysterectomy
    • Myomectomy
  • Laparoscopic Techniques
    • Laparoscopic
    • Myolosis
  • Ablation Techniques
    • Microwave Ablation
    • Cryoablation
    • Ultrasound Ablation
  • Embolization Techniques
  • Others
Breakup by End-User
  • Hospitals
  • Dialysis Centres
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • SWOT
  • Porter's Five Forces
  • Key Indicators for Demand
  • Key Indicators for Price
Trade Data Analysis
  • Major Exporting Countries
    • By Value
    • By Volume
  • Major Importing Countries
    • By Value
    • By Volume
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • Medtronic
  • Boston Scientific Corporation
  • Cooper Surgical Inc.
  • Stryker Corporation
  • Minerva Surgical, Inc
  • AbbVie Inc.
  • Ethicon, Inc.
  • Lumenis Ltd
  • Smith & Nephew PLC
  • Merit Medical Systems, Inc.
  • Hologic, Inc.
  • ConMed Corporation
  • Gynesonics, Inc

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
        1.1.1    Research Objectives
        1.1.2    Key Findings of the Report
    1.2    Limitations of the Study and Scope for Future Research
2    Research Methodology
3    Executive Summary
4    Global Uterine Fibroid Treatment Devices Market 

    4.1    Global Uterine Fibroid Treatment Devices Market Overview
    4.2    Global Uterine Fibroid Treatment Devices Market Analysis 
        4.2.1     Market Overview
            4.2.1.1    Global Uterine Fibroid Treatment Devices Market Historical Value (2015-2021) 
            4.2.1.2    Global Uterine Fibroid Treatment Devices Market Forecast Value (2022-2030)
    4.3    Global Uterine Fibroid Treatment Devices Market by Mode of Treatment 
        4.3.1     Market Overview
            4.3.1.1    Invasive System
            4.3.1.2    Non-Invasive System
            4.3.1.3    Minimally Invasive System 
    4.4    Global Uterine Fibroid Treatment Devices Market by Techniques
        4.4.1     Market Overview
            4.4.1.1    Surgical Techniques 
                4.4.1.1.1    Hysterectomy
                4.4.1.1.2    Myomectomy 
            4.4.1.2    Laparoscopic Techniques 
                4.4.1.2.1    Laparoscopic 
                4.4.1.2.2    Myolosis
            4.4.1.3    Ablation Techniques 
                4.4.1.3.1    Microwave Ablation
                4.4.1.3.2    Cryoablation
                4.4.1.3.3    Ultrasound Ablation
            4.4.1.4    Embolization Techniques
            4.4.1.5    Others
    4.5    Global Uterine Fibroid Treatment Devices Market by End-User 
        4.5.1    Market Overview
            4.5.1.1    Hospitals
            4.5.1.2    Dialysis Centres
            4.5.1.3    Others 
    4.6    Global Uterine Fibroid Treatment Devices Market by Region
        4.6.1    Market Overview
            4.6.1.1    North America 
            4.6.1.2    Europe 
            4.6.1.3    Asia Pacific 
            4.6.1.4    Latin America 
            4.6.1.5    Middle East and Africa 
        4.6.2    North America 
            4.6.2.1    Historical Trend (2015-2021) 
            4.6.2.2    Forecast Trend (2022-2030) 
            4.6.2.3    Break Up by Country 
                4.6.2.3.1    United States of America 
                4.6.2.3.2    Canada 
        4.6.3    Europe 
            4.6.3.1    Historical Trend (2015-2021) 
            4.6.3.2    Forecast Trend (2022-2030) 
            4.6.3.3    Break Up by Country 
                4.6.3.3.1    United Kingdom 
                4.6.3.3.2    Germany 
                4.6.3.3.3    France 
                4.6.3.3.4    Italy 
                4.6.3.3.5    Others 
        4.6.4    Asia Pacific 
            4.6.4.1    Historical Trend (2015-2021) 
            4.6.4.2    Forecast Trend (2022-2030) 
            4.6.4.3    Break Up by Country 
                4.6.4.3.1    China 
                4.6.4.3.2    Japan 
                4.6.4.3.3    India 
                4.6.4.3.4    ASEAN 
                4.6.4.3.5    Australia 
                4.6.4.3.6    Others 
        4.6.5    Latin America 
            4.6.5.1    Historical Trend (2015-2021) 
            4.6.5.2    Forecast Trend (2022-2030) 
            4.6.5.3    Break Up by Country 
                4.6.5.3.1    Brazil 
                4.6.5.3.2    Argentina 
                4.6.5.3.3    Mexico 
                4.6.5.3.4    Others 
        4.6.6    Middle East and Africa 
            4.6.6.1    Historical Trend (2015-2021) 
            4.6.6.2    Forecast Trend (2022-2030) 
            4.6.6.3    Break Up by Country 
                4.6.6.3.1    Saudi Arabia 
                4.6.6.3.2    United Arab Emirates 
                4.6.6.3.3    Nigeria 
                4.6.6.3.4    South Africa 
                4.6.6.3.5    Others   
5    Trade Data Analysis by HS Code- XXXX
6    Regulations and Clinical Assessment

    6.1    Regulatory Capabilities
    6.2    Patent Landscape
    6.3    Clinical Trials
7    Global Uterine Fibroid Treatment Devices Industry Dynamics
    7.1    Industry Drivers and Constraints
    7.2    Porters
    7.3    SWOT Analysis
    7.4    Key Demand Indicator Analysis
    7.5    Key Price Indicator Analysis
    7.6    Industry Events, Initiatives, and Trends
    7.7    Value Chain
8    Global Uterine Fibroid Treatment Devices Distribution Model (Additional Insights)
    8.1    Overview
    8.2    Potential Distributor
    8.3    Key Parameters for Distribution Partner Assessment
9    Supplier Landscape
    9.1    Medtronic
        9.1.1    Company Overview
        9.1.2    Product Portfolio
        9.1.3    Demographic Reach and Achievements
        9.1.4    Mergers and Acquisitions
        9.1.5    Certifications
    9.2    Boston Scientific Corporation 
        9.2.1    Company Overview
        9.2.2    Product Portfolio
        9.2.3    Demographic Reach and Achievements
        9.2.4    Mergers and Acquisitions
        9.2.5    Certifications
    9.3    Cooper Surgical Inc.
        9.3.1    Company Overview
        9.3.2    Product Portfolio
        9.3.3    Demographic Reach and Achievements
        9.3.4    Mergers and Acquisitions
        9.3.5    Certifications
    9.4    Stryker Corporation
        9.4.1    Company Overview
        9.4.2    Product Portfolio
        9.4.3    Demographic Reach and Achievements
        9.4.4    Mergers and Acquisitions
        9.4.5    Certifications
    9.5    Minerva Surgical, Inc 
        9.5.1    Company Overview
        9.5.2    Product Portfolio
        9.5.3    Demographic Reach and Achievements
        9.5.4    Mergers and Acquisitions
        9.5.5    Certifications
    9.6    AbbVie Inc.
        9.6.1    Company Overview
        9.6.2    Product Portfolio
        9.6.3    Demographic Reach and Achievements
        9.6.4    Mergers and Acquisitions
        9.6.5    Certifications
    9.7    Ethicon, Inc.
        9.7.1    Company Overview
        9.7.2    Product Portfolio
        9.7.3    Demographic Reach and Achievements
        9.7.4    Mergers and Acquisitions
        9.7.5    Certifications
    9.8    Lumenis Ltd
        9.8.1    Company Overview
        9.8.2    Product Portfolio
        9.8.3    Demographic Reach and Achievements
        9.8.4    Mergers and Acquisitions
        9.8.5    Certifications
    9.9    Smith & Nephew PLC
        9.9.1    Company Overview
        9.9.2    Product Portfolio
        9.9.3    Demographic Reach and Achievements
        9.9.4    Mergers and Acquisitions
        9.9.5    Certifications
    9.10    Merit Medical Systems, Inc.
        9.10.1    Company Overview
        9.10.2    Product Portfolio
        9.10.3    Demographic Reach and Achievements
        9.10.4    Mergers and Acquisitions
        9.10.5    Certifications
    9.11    Hologic, Inc.
        9.11.1    Company Overview
        9.11.2    Product Portfolio
        9.11.3    Demographic Reach and Achievements
        9.11.4    Mergers and Acquisitions
        9.11.5    Certifications
    9.12    ConMed Corporation
        9.12.1    Company Overview
        9.12.2    Product Portfolio
        9.12.3    Demographic Reach and Achievements
        9.12.4    Mergers and Acquisitions
        9.12.5    Certifications
    9.13    Gynesonics, Inc
        9.13.1    Company Overview
        9.13.2    Product Portfolio
        9.13.3    Demographic Reach and Achievements
        9.13.4    Mergers and Acquisitions
        9.13.5    Certifications
10    Recommendations and Discussion 
11    Pricing Models and Strategies (Additional Insight)

    11.1    Overview
    11.2    Cost Model
        11.2.1    Manufacturing Cost Analysis
        11.2.2    Procurement Cost Analysis
        11.2.3    Clinical Trial Cost Factors
    11.3    Pricing Strategies
        11.3.1    Competitor pricing Analysis
        11.3.2    Key Assessment of Product Attributes
        11.3.3    Pricing Benchmark

Key Questions Answered in the Report

In 2021, the global market attained a value of nearly USD 5.5 billion.

The market is projected to grow at a CAGR of 9.5% between 2022 and 2030.

The market is estimated to witness healthy growth in the forecast period of 2022-2027 to reach USD 12.5 billion by 2030.

The rising cases of uterine fibroid and minimally invasive procedures are expected to drive the global uterine fibroid treatment devices market.

The most commonly suggested treatment by doctors like MR-guided focused ultrasound, which results in quick recovery, less pain, and efficient results is expected to increase the demand for this market.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific, with North America accounting for the largest share in the market.

The key companies involved in this market are Medronics, Bosteon Scientific Corporation, Cooper surgical Inc., Stryker Corporation, Minerva Surgical, Inc., AbbiVie Inc., Ethicon Inc., Lumenis Ltd, Smith & Nephew PLC, Merit Medical System, Inc., Hologics, Inc., CONMED Corporation, and Gynesonics, Inc., among others.

If the fibroid is about 9-10 cm or 4 inches diameter and above need, it needs to be removed surgically.

Lupron is usually prescribed which reduces the oestrogen levels before the surgery.

Purchase Full Report

Mini Report

$2499
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$6499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$7999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER